How did Actinium's operating expenses trend in Q4 2024?

Actinium Pharmaceuticals Inc.'s operating expenses in Q4 2024 are not currently available. However, based on the information available, the company's financial results for Q3 2024 can provide some insights into its potential operating expense trends.

1. **Comparison with Previous Quarter**: Actinium's Q3 2024 net loss was $11.57 million, which is a reduction from the $13.28 million net loss in Q3 2023. This suggests a potential decrease in operating expenses, as the company reported lower research and development expenses, which dropped to $9.8 million from $11.6 million year-over-year. General and administrative expenses were higher than in the previous year, but the overall trend indicates a reduction in losses and potentially lower operating expenses.
2. **Strategic Restructuring**: The company has been actively managing costs through strategic restructuring. For example, Actinium has reduced its workforce by 60% to aim for $7.5 million in annual savings. This significant reduction in personnel costs could have a positive impact on operating expenses in the long term.
3. **Cash Position and Funding**: Actinium's cash and cash equivalents increased to $23.3 million as of December 31, 2024. The company has also raised $29.3 million through the sale of common stock, enhancing its cash position to $78.7 million. This financial stability could provide Actinium with the flexibility to manage its operating expenses effectively.

In conclusion, while specific Q4 2024 operating expense data is not available, the trends indicated by the Q3 financial results and strategic initiatives suggest that Actinium may have experienced a decrease in operating expenses compared to the previous year. However, further details would be required to confirm this trend.